U.S. shares of Novartis AG rose in the extended session Wednesday after a Food and Drug Administration advisory panel unanimously recommended that the agency approve one of its cancer drugs. U.S.-traded Novartis shares rose 1.7% to $84.60 after hours. The company said the FDA’s Oncologic Drugs Advisory Committee voted 10 to 0 in favor of approving Novartis’s drug tisagenlecleucel for the treatment of children and young adults with B-cell acute lymphoblastic leukemia, a type of blood cancer. The FDA is not obligated to follow the recommendations of its advisory panels but generally does.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News